Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 results of relacorilant + nabpaclitaxel in patients with recurrent, platinum-resistant ovarian cancer with and without prior bevacizumab
    Meeting Abstract

    Colombo, N.; Van Gorp, T.; Matulonis, U.; Oaknin, A.; Grisham, R.; Fleming, G.; Olawaiye, A.; Tudor, I. C.; Pashova, H.; Lorusso, D.
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Updated safety of lenvatinib + pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775
    Meeting Abstract

    Makker, V.; Colombo, N.; Casado Herráez, A.; Monk, B.; Mackay, H.; Santin, A.; Miller, D.; Moore, R.; Ray-Coquard, I.; Shapira-Frommer, R.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Germline pathogenic variants in DNA repair genes and endometrial cancer risk
    Meeting Abstract

    Gordhandas, S.; Rios-Doria, E.; Cadoo, K.; Catchings, A.; Maio, A.; Kemel, Y.; Manning-Geist, B.; Sia, T.; Roche, K. L.; Leitao, M.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Molecular stratification of ovarian clear cell carcinoma predicts clinical outcomes
    Meeting Abstract

    Gordhandas, S.; Manning-Geist, B.; Hodgson, A.; Zhou, Q.; Iasonos, A.; Chi, D.; Momeni-Boroujeni, A.; Abu-Rustum, N.; Leitao, M.; Roche, K. L.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study
    Meeting Abstract

    Gien, L.; Enserro, D.; Block, M.; Waggoner, S.; Duska, L.; Hendrickson, A. W.; Thaker, P.; Backes, F.; Bottsford-Miller, J.; Muller, C.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Overall survival results from Ariel3: A phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
    Meeting Abstract

    Coleman, R. L.; Oza, A.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.; Clamp, A.; Scambia, G.; more...
    International Journal of Gynecological Cancer (2022)

    Fulltext@MSK | Save
  • Endogenous retrotransposable elements induction in SMARCA4-deficient ovarian cancer is associated with immunomodulatory changes in the tumor microenvironment
    Meeting Abstract

    Brodeur, M. N.; Sun, S.; Zhu, Y.; Greenbaum, B.; Weigelt, B.; Zamarin, D.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets
    Meeting Abstract

    Nacev, B. A.; Sanchez-Vega, F.; Smith, S.; Antonescu, C.; Rosenbaum, E.; Shi, H.; Tang, C.; Socci, N.; Rana, S.; Gularte-Merida, R.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab versus treatment of physician's choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup
    Meeting Abstract

    Yonemori, K.; Fujiwara, K.; Hasegawa, K.; Yunokawa, M.; Ushijima, K.; Suzuki, S.; Shikama, A.; Minobe, S.; Usami, T.; Kim, J. W.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
    Meeting Abstract

    Park, J. O.; Meng, D. T. W.; Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Cassier, P.; Kamath, S. D.; Dotan, E.; Kim, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save